Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Exploratory Study of Durvalumab (MEDI4736) in HIV-1 Patients With Advanced Solid Tumors.

NCT03094286 is registered in ClinicalTrials.gov with Spanish Lung Cancer Group as lead sponsor.

NCT NCT03094286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03094286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Exploratory Study of Durvalumab (MEDI4736) in HIV-1 Patients With Advanced Solid Tumors.
Lead sponsor
Spanish Lung Cancer Group
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2017
Completion date
March 22, 2022
Enrollment
20 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, hiv